Novartis Aktie

110,34 EUR -4,22 EUR -3,68 %

16:32:38

XETRA

101,78 CHF -4,00 CHF -3,78 %

16:49:48

SWX

Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.214,95 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

12.05.25BenzingaAlcon Earnings Preview

09.05.25ZacksHere's Why Novartis (NVS) is a Strong Momentum Stock

08.05.25ZacksAhead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

07.05.25Financial TimesChina sees global turmoil as opportunity to be ‘business friendly’, says Novartis chief

05.05.25BenzingaBioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion

05.05.25ZacksNovartis (NVS) is a Great Momentum Stock: Should You Buy?

05.05.25ZacksWhy Novartis (NVS) is a Great Dividend Stock Right Now

01.05.25ZacksDo Options Traders Know Something About Alcon Stock We Don't?

30.04.25BenzingaNovartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

30.04.25ZacksWhy Novartis (NVS) is a Top Value Stock for the Long-Term

30.04.25GlobeNewswireNovartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

30.04.25Dow JonesPress Release: Novartis to acquire Regulus -2-

30.04.25Dow JonesPress Release: Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause o...

29.04.25BenzingaNovartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance

29.04.25ZacksCompared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics

29.04.25ZacksNovartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up

29.04.25Dow JonesPress Release: Novartis continues strong momentum -3-

29.04.25Dow JonesPress Release: Novartis continues strong momentum -2-

29.04.25GlobeNewswireNovartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

29.04.25Dow JonesPress Release: Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

28.04.25BenzingaEarnings Preview For Novartis

23.04.25ZacksWhy Novartis (NVS) is a Top Momentum Stock for the Long-Term

21.04.25ZacksNovartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?

18.04.25ZacksWhy Novartis (NVS) is a Top Dividend Stock for Your Portfolio

14.04.25ZacksNovartis (NVS) Surges 4.0%: Is This an Indication of Further Gains?

14.04.25ZacksThe Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

11.04.25BenzingaNovartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties

11.04.25Financial TimesSwiss drugmaker Novartis to invest $23bn in US manufacturing and R&D

11.04.25RTE.ieNovartis plans to invest $23 billion in US sites

11.04.25Business TimesNovartis pledges US$23 billion US investment as tariffs loom

03.04.25BenzingaNovartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year

03.04.25PR NewswireNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

03.04.25GlobeNewswireNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

03.04.25Dow JonesPress Release: Novartis receives FDA accelerated -2-

03.04.25Dow JonesPress Release: Novartis receives FDA accelerated approval for Vanrafia(R) (atrasentan), the first and only selective endothelin A receptor antagonist for pro...

02.04.25ZacksNovartis (NVS) Could Be a Great Choice

01.04.25ZacksThe Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals

31.03.25GlobeNewswireNovartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

31.03.25Dow JonesPress Release: Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from...

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.